| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
|
Hadji, P.
|
|
|
27 |
3 |
p. 379-390
|
article
|
| 2 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.
|
|
|
27 |
3 |
p. 417-423
|
article
|
| 3 |
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
|
Tolcher, A.W.
|
|
|
27 |
3 |
p. 526-532
|
article
|
| 4 |
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
|
Chi, K.N.
|
|
|
27 |
3 |
p. 454-460
|
article
|
| 5 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer †
|
Ueno, M.
|
|
|
27 |
3 |
p. 502-508
|
article
|
| 6 |
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study
|
Thomsen, F.B.
|
|
|
27 |
3 |
p. 460-466
|
article
|
| 7 |
Being molecular in the molecular age
|
Raghupathy, R.
|
|
|
27 |
3 |
p. 367-368
|
article
|
| 8 |
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
|
Niikura, N.
|
|
|
27 |
3 |
p. 480-487
|
article
|
| 9 |
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
|
Ahmed, K.A.
|
|
|
27 |
3 |
p. 434-441
|
article
|
| 10 |
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial †
|
Bourgier, C.
|
|
|
27 |
3 |
p. 474-480
|
article
|
| 11 |
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
|
Ramalingam, S.S.
|
|
|
27 |
3 |
p. 423-429
|
article
|
| 12 |
Editorial board
|
|
|
|
27 |
3 |
p. ii-iii
|
article
|
| 13 |
Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin
|
Kim, S.J.
|
|
|
27 |
3 |
p. 508-513
|
article
|
| 14 |
Genetic testing in a cohort of young patients with HER2-amplified breast cancer
|
Eccles, D.M.
|
|
|
27 |
3 |
p. 467-473
|
article
|
| 15 |
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
|
Kanameishi, S.
|
|
|
27 |
3 |
p. 546-547
|
article
|
| 16 |
Implications of polygenic risk for personalised colorectal cancer screening
|
Frampton, M.J.E.
|
|
|
27 |
3 |
p. 429-434
|
article
|
| 17 |
Integration between oncology and palliative care: does one size fit all?
|
Verna, L.
|
|
|
27 |
3 |
p. 549
|
article
|
| 18 |
Is it possible to encourage hope in non-advanced cancer patients? We must try
|
Ripamonti, C.I.
|
|
|
27 |
3 |
p. 513-519
|
article
|
| 19 |
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy
|
Tannock, I.F.
|
|
|
27 |
3 |
p. 545-546
|
article
|
| 20 |
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
|
Rugo, H.S.
|
|
|
27 |
3 |
p. 519-525
|
article
|
| 21 |
Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples
|
Piskorz, A.M.
|
|
|
27 |
3 |
p. 532-539
|
article
|
| 22 |
Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group
|
Spano, J.-P.
|
|
|
27 |
3 |
p. 397-408
|
article
|
| 23 |
Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseases
|
Radice, P.
|
|
|
27 |
3 |
p. 369-370
|
article
|
| 24 |
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) †
|
Motzer, R.J.
|
|
|
27 |
3 |
p. 441-448
|
article
|
| 25 |
Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancer
|
Kang, B.W.
|
|
|
27 |
3 |
p. 494-501
|
article
|
| 26 |
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
|
Lorusso, D.
|
|
|
27 |
3 |
p. 487-493
|
article
|
| 27 |
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
|
Chen, J.
|
|
|
27 |
3 |
p. 409-416
|
article
|
| 28 |
Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al.
|
Lambertini, M.
|
|
|
27 |
3 |
p. 548-549
|
article
|
| 29 |
Reply to the letter to the editor ‘How much evidence isn't in evidence-based guidelines?’ by Johnson et al.
|
Cherny, N.I.
|
|
|
27 |
3 |
p. 550-551
|
article
|
| 30 |
Reply to the letter to the editor ‘Integration between oncology and palliative care: does one size fit all?’ by Verna et al.
|
Hui, D.
|
|
|
27 |
3 |
p. 549-550
|
article
|
| 31 |
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
|
Fleury, I.
|
|
|
27 |
3 |
p. 390-397
|
article
|
| 32 |
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents
|
Saad, E.D.
|
|
|
27 |
3 |
p. 373-378
|
article
|
| 33 |
Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?
|
Dhermain, F.
|
|
|
27 |
3 |
p. 371-372
|
article
|
| 34 |
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer
|
Rothermundt, C.
|
|
|
27 |
3 |
p. 544-545
|
article
|
| 35 |
Table of Contents
|
|
|
|
27 |
3 |
p. iv-vi
|
article
|
| 36 |
TP53 mutational status is predictive of pazopanib response in advanced sarcomas
|
Koehler, K.
|
|
|
27 |
3 |
p. 539-543
|
article
|
| 37 |
Trabectedin is an effective second-line treatment in soft tissue sarcoma patients
|
Peugniez, C.
|
|
|
27 |
3 |
p. 551-552
|
article
|
| 38 |
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) †
|
De Santis, M.
|
|
|
27 |
3 |
p. 449-454
|
article
|
Journal description